Li Y - Search Results

1

Real-world evidence of avatrombopag for the treatment of immune thrombocytopenia intolerant or ineffective to eltrombopag/hetrombopag.

Tian H, Zhou L, Dai JW, Li Y, Gu CY, Kong DQ, Yu ZQ, Liu XF, Yin J. Tian H, et al. Among authors: li y. Br J Haematol. 2024 Oct 4. doi: 10.1111/bjh.19800. Online ahead of print. Br J Haematol. 2024. PMID: 39367620

2

Bortezomib, a promising alternative for patients with refractory or relapsed thrombotic thrombocytopenic purpura after rituximab treatment.

Yin J, Tian H, Kong D, Li Y, Gu C, Wang Z, Wu D, Yu Z. Yin J, et al. Among authors: li y. Br J Haematol. 2022 Nov;199(4):619-622. doi: 10.1111/bjh.18430. Epub 2022 Sep 8. Br J Haematol. 2022. PMID: 36076349 No abstract available.

3

Successful treatment of acquired amegakaryocytic thrombocytopenia with eltrombopag and immunosuppressant.

Tian H, Kong D, Li Y, Gu C, Yu Z, Wang Z, Wu D, Yin J. Tian H, et al. Among authors: li y. Platelets. 2022 Aug 18;33(6):951-953. doi: 10.1080/09537104.2021.2012140. Epub 2021 Dec 16. Platelets. 2022. PMID: 34915800 Free article.

4

Bortezomib provides favorable efficacy in type 3 acquired von willebrand syndrome related to lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia.

Kong D, Li Y, Fu C, Hou M, Yan L, Shang J, Wang Z, Yin J, Yu Z, Wu D. Kong D, et al. Among authors: li y. Leuk Lymphoma. 2022 Feb;63(2):491-494. doi: 10.1080/10428194.2021.1992766. Epub 2021 Oct 20. Leuk Lymphoma. 2022. PMID: 34668450 No abstract available.

5

Aberrant hypomethylation of DDX43 promoter in myelodysplastic syndrome.

Chen Q, Lin J, Yao DM, Qian J, Qian W, Yang J, Chai HY, Ma JC, Deng ZQ, Wang CZ, Li Y. Chen Q, et al. Among authors: li y. Br J Haematol. 2012 Jul;158(2):293-296. doi: 10.1111/j.1365-2141.2012.09138.x. Epub 2012 May 5. Br J Haematol. 2012. PMID: 22563673 Free article. No abstract available.

6

Initial Treatment Patterns and Survival Outcomes of Mantle Cell Lymphoma Patients Managed at Chinese Academic Centers in the Rituximab Era: A Real-World Study.

Wu M, Li Y, Huang H, Xu W, Wang Y, Huang H, Zhao W, Liu S, Xu P, Chen Z, Zhu J, Song Y, Ruan J, Wu D. Wu M, et al. Among authors: li y. Front Oncol. 2022 Jan 4;11:770988. doi: 10.3389/fonc.2021.770988. eCollection 2021. Front Oncol. 2022. PMID: 35059312 Free PMC article.

7

Hypomethylation of PRAME promoter is associated with poor prognosis in myelodysplastic syndrome.

Qian J, Zhu ZH, Lin J, Ming Yao DM, Li Y, Yang J, Wang CZ. Qian J, et al. Among authors: li y. Br J Haematol. 2011 Jul;154(1):153-5. doi: 10.1111/j.1365-2141.2011.08585.x. Epub 2011 Apr 22. Br J Haematol. 2011. PMID: 21517806 Free article. No abstract available.

8

Overexpressed let-7a-3 is associated with poor outcome in acute myeloid leukemia.

Li Y, Lin J, Yang J, Qian J, Qian W, Yao DM, Deng ZQ, Liu Q, Chen XX, Xie D, An C, Tang CY. Li Y, et al. Leuk Res. 2013 Dec;37(12):1642-7. doi: 10.1016/j.leukres.2013.09.022. Epub 2013 Sep 30. Leuk Res. 2013. PMID: 24138945

9

Overexpression of miR-378 is frequent and may affect treatment outcomes in patients with acute myeloid leukemia.

Qian J, Lin J, Qian W, Ma JC, Qian SX, Li Y, Yang J, Li JY, Wang CZ, Chai HY, Chen XX, Deng ZQ. Qian J, et al. Among authors: li jy, li y. Leuk Res. 2013 Jul;37(7):765-8. doi: 10.1016/j.leukres.2013.03.014. Epub 2013 Apr 11. Leuk Res. 2013. PMID: 23582927

10

Abnormal methylation of GRAF promoter Chinese patients with acute myeloid leukemia.

Qian J, Qian Z, Lin J, Yao DM, Chen Q, Li Y, Ji RB, Yang J, Xiao GF, Wang YL. Qian J, et al. Among authors: li y. Leuk Res. 2011 Jun;35(6):783-6. doi: 10.1016/j.leukres.2010.10.013. Epub 2010 Nov 11. Leuk Res. 2011. PMID: 21074269

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

235,681 results

Search Page

Filters